TSLA
Tesla
-- 292.980 NVDA
NVIDIA
-- 124.920 PLTR
Palantir
-- 84.920 MSTR
Strategy
-- 255.430 SOUN
SoundHound AI
-- 10.820 
NEWS
Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million
Monday, 2nd December at 4:05 pm
AUSTIN, TEXAS / ACCESSWIRE / December 2, 2024 / Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open market by certain related parties including Chief Financial Officer Noel Knape, totaling approximately $1 million. Additional details can be found on the Form 8-K filed today by the Company under Item 8.01 Other Events.
"Our senior management team has purchased shares in the open market, reflecting high confidence in our strategy and expectation to create long-term shareholder value," said Ben Sexson, Chief Executive Officer of Monogram. "With the funding secured from our recent offering, we are optimistic about our ability to reach our key milestones in the months ahead."
Upcoming Milestones
Issue-specific meeting with the FDA by December 2024.
Seek to obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals.
Seek to obtain FDA clearance for the mBôs™ TKA System.
Continue exploring domestic relationships.
Seek to continue expanding international relationships (the Company will be exhibiting at Arab Health in January 2025).
Monday, 2nd December at 4:05 pm
AUSTIN, TEXAS / ACCESSWIRE / December 2, 2024 / Monogram Technologies Inc. (NASDAQ: MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open market by certain related parties including Chief Financial Officer Noel Knape, totaling approximately $1 million. Additional details can be found on the Form 8-K filed today by the Company under Item 8.01 Other Events.
"Our senior management team has purchased shares in the open market, reflecting high confidence in our strategy and expectation to create long-term shareholder value," said Ben Sexson, Chief Executive Officer of Monogram. "With the funding secured from our recent offering, we are optimistic about our ability to reach our key milestones in the months ahead."
Upcoming Milestones
Issue-specific meeting with the FDA by December 2024.
Seek to obtain regulatory clearance to conduct clinical trials in India with strategic partner Shalby Hospitals.
Seek to obtain FDA clearance for the mBôs™ TKA System.
Continue exploring domestic relationships.
Seek to continue expanding international relationships (the Company will be exhibiting at Arab Health in January 2025).
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment